why choose us

First received: September 16, 2022

Clinical Trial: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Brain Metastases

Study Type: INTERVENTIONAL


Official Title: Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer

Brief Summary: This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab.The combined use of SRS with the three drugs is considered investigational.

Read more